Apr 25, 2018 - Three biotechs reported devastating clinical trial failures this month. Here are the important takeaways.
Apr 25, 2018 - Lilly's first-quarter results looked good. Is it time to buy the big pharma stock?
Apr 24, 2018 - Eli Lilly (LLY) beats estimates for both earnings and sales in Q1 and raises guidance for 2018. Shares rise in pre-market trading.
Apr 20, 2018 - Highly anticipated events expected in the weeks ahead could set these three biotechs up for long-term success.
Apr 20, 2018 - Lilly's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
Apr 16, 2018 - Incyte’s phase 3 Epacadostat trial wasn’t so hot, and stocks all across biotech are feeling the burn.
Apr 16, 2018 - With a key pipeline drug nixed, Incyte has a few more question marks on the horizon than it did before.
Apr 16, 2018 - The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte
Apr 13, 2018 - Investor confidence in epacadostat was through the roof, and the drug's phase 3 flop crushed the stock in a big way.
Apr 13, 2018 - Novartis and Alexion announce respective acquisitions of AveXis and Wilson Therapeutics for a pipeline boost. We suggest four stocks as hot acquisition picks this year.